InVivoSIM anti-human FGFR2b (CD332) (Bemarituzumab Biosimilar)

About InVivoSIM anti-human FGFR2b (CD332) (Bemarituzumab Biosimilar)

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody, Bemarituzumab, making it ideal for research use. Bemarituzumab is a humanized, afucosylated IgG1κ anti-human FGFR2b (CD332) antibody, which reacts with the fibroblast growth factor receptor 2 IIIb isoform (FGFR2b) of FGFR2. FGFR2 is a member of a family of four FGF receptors that interact with over 20 different fibroblast growth factors (FGFs), each of which shows relatively unique and restricted expression to specific tissues, cell types, and/or developmental stages. FGF7, FGF10, and FGF22 are the main ligands of FGFR2b. FGFR2b is expressed in epithelial tissues such as the stomach and skin and is often found overexpressed in gastric cancers. FGF-FGFR2 signaling is involved in many cancers, such as gastric, breast, ovarian, endometrial, lung, and bile duct cancers. Bemarituzumab has recently been introduced for the therapeutic blockade of FGFR2b signaling. This antibody acts through a two-pronged approach: in addition to blocking FGFR2b, the afucosylated structure of bemarituzumab triggers the activation of FcγRIIIa (CD16a), which increases the affinity of bemarituzumab for NK cells, thereby enhancing its antibody-dependent cellular cytotoxicity (ADCC) effects against FGFR2b-expressing tumor cells. In combination with anti-cancer experimental therapeutics, bemarituzumab is documented to exhibit substantial synergism in vivo with immune checkpoint blockage via anti-PD-1 or chemotherapy.